![Open Access](/resources/images/iconopenaccess.png)
Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer
- Authors:
- Lyndsay V. Rhodes
- Syreeta L. Tilghman
- Stephen M. Boue
- Shuchun Wang
- Hafez Khalili
- Shannon E. Muir
- Melyssa R. Bratton
- Qiang Zhang
- Guangdi Wang
- Matthew E. Burow
- Bridgette M. Collins-Burow
-
Affiliations: Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA, United States Department of Agriculture, Xavier University of Louisiana, New Orleans, LA 70125, USA, Department of Pharmacology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA, RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA, RCMI Cancer Research Center, Xavier University of Louisiana, New Orleans, LA 70125, USA - Published online on: October 24, 2011 https://doi.org/10.3892/ol.2011.460
- Pages: 163-171
This article is mentioned in:
Abstract
![]() |
![]() |
Reis-Filho JS and Tutt AN: Triple negative tumours: a critical review. Histopathology. 52:108–118. 2008. View Article : Google Scholar | |
Hu Z, Fan C, Oh DS, et al: The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 7:962006. View Article : Google Scholar : PubMed/NCBI | |
Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progeste- rone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a popu- lation-based study from the California cancer registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar | |
Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI | |
Gail MH, Anderson WF, Garcia-Closas M and Sherman ME: Absolute risk models for subtypes of breast cancer. J Natl Cancer Inst. 99:1657–1659. 2007. View Article : Google Scholar : PubMed/NCBI | |
Reis-Filho JS, Westbury C and Pierga JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J Clin Pathol. 59:225–231. 2006. View Article : Google Scholar : PubMed/NCBI | |
Messina M: A brief historical overview of the past two decades of soy and isoflavone research. J Nutr. 140:1350S–1354S. 2010. View Article : Google Scholar : PubMed/NCBI | |
Murkies AL, Wilcox G and Davis SR: Clinical review 92: Phytoestrogens. J Clin Endocrinol Metab. 83:297–303. 1998. View Article : Google Scholar : PubMed/NCBI | |
Tham DM, Gardner CD and Haskell WL: Clinical review 97: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 83:2223–2235. 1998.PubMed/NCBI | |
Humfrey CD: Phytoestrogens and human health effects: weighing up the current evidence. Nat Toxins. 6:51–59. 1998. View Article : Google Scholar : PubMed/NCBI | |
Collins-Burow BM, Burow ME, Duong BN and McLachlan JA: Estrogenic and antiestrogenic activities of flavonoid phytochemicals through estrogen receptor binding-dependent and -independent mechanisms. Nutr Cancer. 38:229–244. 2000. View Article : Google Scholar | |
Collins BM, McLachlan JA and Arnold SF: The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids. 62:365–372. 1997. View Article : Google Scholar : PubMed/NCBI | |
Fournier DB, Erdman JW Jr and Gordon GB: Soy, its components, and cancer prevention: a review of the in vitro, animal, and human data. Cancer Epidemiol Biomarkers Prev. 7:1055–1065. 1998.PubMed/NCBI | |
Barnes S: The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res Treat. 46:169–179. 1997. View Article : Google Scholar : PubMed/NCBI | |
Lamartiniere CA, Zhang JX and Cotroneo MS: Genistein studies in rats: potential for breast cancer prevention and reproductive and developmental toxicity. Am J Clin Nutr. 68:1400S–1405S. 1998.PubMed/NCBI | |
Diel P, Smolnikar K, Schulz T, Laudenbach-Leschowski U, Michna H and Vollmer G: Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium. Hum Reprod. 16:997–1006. 2001. View Article : Google Scholar : PubMed/NCBI | |
Boue SM, Carter CH, Ehrlich KC and Cleveland TE: Induction of the soybean phytoalexins coumestrol and glyceollin by Aspergillus. J Agric Food Chem. 48:2167–2172. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bhattacharyya M and Ward EWB: Resistance, susceptibility and accumulation of glyceollins I-III in soybean organs inoculated with Phytophthora megasperma f. sp. Glycinea. Physiol and Mol Plant Pathol. 29:227–237. 1986. View Article : Google Scholar | |
Boue SM, Wiese TE, Nehls S, Burow ME, Elliott S, Carter-Wientjes CH, Shih BY, McLachlan JA and Cleveland TE: Evaluation of the estrogenic effects of legume extracts containing phytoestrogens. J Agric Food Chem. 51:2193–2199. 2003. View Article : Google Scholar : PubMed/NCBI | |
Graham TL and Graham MY: Glyceollin elicitors induce major but distinctly different shifts in isoflavonoid metabolism in proximal and distal soybean cell populations. Mol Plant Microbe Interact. 4:60–68. 1991. View Article : Google Scholar | |
Burow ME, Boue SM, Collins-Burow BM, et al: Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab. 86:1750–1758. 2001. | |
Salvo VA, Boue SM, Fonseca JP, et al: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res. 12:7159–7164. 2006. View Article : Google Scholar : PubMed/NCBI | |
Rhodes LV, Muir SE, Elliott S, et al: Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat. 121:293–300. 2010. View Article : Google Scholar : PubMed/NCBI | |
Burow ME, Tang Y, Collins-Burow BM, et al: Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells. Carcinogenesis. 20:2057–2061. 1999. View Article : Google Scholar : PubMed/NCBI | |
Gao X, Gulari E and Zhou X: In situ synthesis of oligonucleotide microarrays. Biopolymers. 73:579–596. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhu Q, Hong A, Sheng N, et al: microParaflo biochip for nucleic acid and protein analysis. Methods Mol Biol. 382:287–312. 2007. View Article : Google Scholar : PubMed/NCBI | |
Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI | |
Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar | |
Winter J and Diederichs S: MicroRNA biogenesis and cancer. Methods Mol Biol. 676:3–22. 2011. View Article : Google Scholar | |
Allen KE and Weiss GJ: Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther. 9:3126–3136. 2011. View Article : Google Scholar : PubMed/NCBI | |
Gandellini P, Profumo V, Folini M and Zaffaroni N: MicroRNAs as new therapeutic targets and tools in cancer. Expert Opin Ther Targets. 15:265–279. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nana-Sinkam SP and Croce CM: MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs. IDrugs. 13:843–846. 2011.PubMed/NCBI | |
Ma L and Weinberg RA: MicroRNAs in malignant progression. Cell Cycle. 7:570–572. 2008. View Article : Google Scholar | |
O'Day E and Lal A: MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12:2012011. | |
Gregory PA, Bracken CP, Bert AG and Goodall GJ: MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 7:3112–3118. 2008. View Article : Google Scholar : PubMed/NCBI | |
Korpal M and Kang Y: The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar : PubMed/NCBI | |
Chen J, Wang L, Matyunina LV, Hill CG and McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tryndyak VP, Beland FA and Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 126:2575–2583. 2011.PubMed/NCBI | |
Ota D, Mimori K, Yokobori T, et al: Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol. 38:955–962. 2011.PubMed/NCBI | |
Patel JB, Appaiah HN, Burnett RM, et al: Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 30:1290–1301. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li J, Liang S, Yu H, Zhang J, Ma D and Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 119:543–548. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li J, Liang SH and Lu X: Potential role of ezrin and its related microRNA in ovarian cancer invasion and metastasis. Zhonghua Fu Chan Ke Za Zhi. 45:787–792. 2011.PubMed/NCBI | |
Wu N, Zhao X, Liu M, et al: Role of microRNA-26b in glioma development and its mediated regulation on EphA2. PLoS One. 6:e162642011. View Article : Google Scholar : PubMed/NCBI | |
Liu XX, Li XJ, Zhang B, et al: MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11. FEBS Lett. 585:1363–1367. 2011. View Article : Google Scholar : PubMed/NCBI | |
Martinez I, Cazalla D, Almstead LL, Steitz JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011. View Article : Google Scholar : PubMed/NCBI | |
Villarreal G Jr, Oh DJ, Kang MH and Rhee DJ: Coordinated Regulation of Extracellular Matrix Synthesis by the MicroRNA-29 Family in the Trabecular Meshwork. Invest Ophthalmol Vis Sci. 52:3391–3397. 2011. View Article : Google Scholar : PubMed/NCBI | |
Maurer B, Stanczyk J, Jungel A, et al: MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 62:1733–1743. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Hassan MQ, Jafferji M, et al: Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem. 284:15676–15684. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ott CE, Grunhagen J, Jager M, et al: MicroRNAs differentially expressed in postnatal aortic development downregulate elastin via 3′ UTR and coding-sequence binding sites. PLoS One. 6:e162502011.PubMed/NCBI | |
Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI | |
Park SY, Lee JH, Ha M, Nam JW and Kim VN: miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol. 16:23–29. 2009. View Article : Google Scholar : PubMed/NCBI | |
Hashimoto Y, Akiyama Y, Otsubo T, Shimada S and Yuasa Y: Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 31:777–784. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li D, Zhao Y, Liu C, et al: Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 7:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Wang J, Ma H, Zhang J and Zhou X: Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. March 10–2011.(E-pub ahead of print). | |
Sekiya Y, Ogawa T, Iizuka M, Yoshizato K, Ikeda K and Kawada N: Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon-beta-induced inhibition of hepatic stellate cell proliferation. J Cell Physiol. 226:2535–2542. 2011. View Article : Google Scholar : PubMed/NCBI | |
Liu L, Chen L, Xu Y, Li R and Du X: microRNA-195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun. 400:236–240. 2011. View Article : Google Scholar : PubMed/NCBI | |
Tili E, Michaille JJ, Adair B, et al: Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis. 31:1561–1566. 2011. View Article : Google Scholar : PubMed/NCBI | |
Pan J, Hu H, Zhou Z, et al: Tumor-suppressive mir-663 gene induces mitotic catastrophe growth arrest in human gastric cancer cells. Oncol Rep. 24:105–112. 2011.PubMed/NCBI | |
Zhang X, Yu H, Lou JR, et al: MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells. J Biol Chem. 286:1429–1435. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ory B, Ramsey MR, Wilson C, et al: A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest. 121:809–820. 2011. View Article : Google Scholar : PubMed/NCBI | |
Du L, Schageman JJ, Subauste MC, et al: miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009. View Article : Google Scholar : PubMed/NCBI | |
Arndt GM, Dossey L, Cullen LM, et al: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer. 9:3742009. View Article : Google Scholar : PubMed/NCBI | |
Li Q, Wang G, Shan JL, et al: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol. 25:164–171. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mees ST, Mardin WA, Sielker S, et al: Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol. 16:2339–2350. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wingett DG, Vestal RE, Forcier K, Hadjokas N and Nielson CP: CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat. 50:27–36. 1998. View Article : Google Scholar : PubMed/NCBI | |
Castilla MA, Moreno-Bueno G, Romero-Perez L, et al: Micro- RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 223:72–80. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bonci D: MicroRNA-21 as therapeutic target in cancer and cardiovascular disease. Recent Pat Cardiovasc Drug Discov. 5:156–161. 2011. View Article : Google Scholar : PubMed/NCBI | |
Radojicic J, Zaravinos A, Vrekoussis T, Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI | |
Mei M, Ren Y, Zhou X, et al: Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells. Technol Cancer Res Treat. 9:77–86. 2011. View Article : Google Scholar : PubMed/NCBI | |
Gong C, Yao Y, Wang Y, et al: Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 286:19127–19137. 2011. View Article : Google Scholar : PubMed/NCBI | |
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI | |
Qi L, Bart J, Tan LP, et al: Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 9:1632009. View Article : Google Scholar : PubMed/NCBI | |
Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A and Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 283:1026–1033. 2008. View Article : Google Scholar : PubMed/NCBI | |
Song B, Wang C, Liu J, et al: MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res. 29:292010. View Article : Google Scholar : PubMed/NCBI | |
Zhu S, Si ML, Wu H and Mo YY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 282:14328–14336. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zhu S, Wu H, Wu F, Nie D, Sheng S and Mo YY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18:350–359. 2008. View Article : Google Scholar : PubMed/NCBI | |
Russell RL, Pedersen AN, Kantor J, et al: Relationship of nm23 to proteolytic factors, proliferation and motility in breast cancer tissues and cell lines. Br J Cancer. 78:710–717. 1998. View Article : Google Scholar : PubMed/NCBI | |
Kokkinos MI, Wafai R, Wong MK, Newgreen DF, Thompson EW and Waltham M: Vimentin and epithelial-mesenchymal transition in human breast cancer – observations in vitro and in vivo. Cells Tissues Organs. 185:191–203. 2007. | |
Joglekar MV, Patil D, Joglekar VM, et al: The miR-30 family microRNAs confer epithelial phenotype to human pancreatic cells. Islets. 1:137–147. 2009. View Article : Google Scholar : PubMed/NCBI |